{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026275","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-08-06T20:16:26+00:00","discovered_at":"2026-08-06T20:18:00.324379+00:00","generated_at":"2026-08-06T20:20:10.882551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phio Pharma Q2 net loss $4.1M; cash $13.0M; PH-762 Phase 1b completed","bullets":["Net loss of $4.1M for Q2 2026 vs $2.2M in Q2 2025, driven by higher R&D spend.","Cash and equivalents $13.0M at June 30, 2026, down from $21.0M at Dec 31, 2025.","R&D expenses $3.1M in Q2, up 187% YoY on nonclinical toxicology and CMC costs.","Phase 1b trial of PH-762 completed; FDA meeting requested in Q3 2026 for next steps.","Established ATM equity offering up to $6.36M in April 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026275","json":"https://secwatch.observer/filing/0001437749-26-026275.json","markdown":"https://secwatch.observer/filing/0001437749-26-026275.md","text":"https://secwatch.observer/filing/0001437749-26-026275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/0001437749-26-026275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/phio20260519_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:10.882551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}